Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus who were, or were not, on antihyperglycaemic agents at screening

被引：0
|
作者：
Gonzalez-Galvez, G. [1 ]
Jodar, E. [2 ]
Kim, K. [3 ]
Alba, M. [4 ]
Tong, C. [4 ]
Meininger, G. [4 ]
机构：
[1] Inst Jalisciense Invest Diabet & Obesidad, Guadalajara, Jalisco, Mexico
[2] Hosp Quiron, Dept Endocrinol, Madrid, Spain
[3] Dongguk Univ, Sch Med, Ilsan Hosp, Dept Internal Med, Goyang, South Korea
[4] Janssen Res & Dev LLC, Raritan, NJ USA
来源：
DIABETOLOGIA | 2014年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
853
引用
收藏
页码：S347 / S348
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
    Hiroaki Iijima
    Takayuki Kifuji
    Nobuko Maruyama
    Nobuya Inagaki
    [J]. Advances in Therapy, 2015, 32 : 768 - 782
  • [22] Efficacy and safety of sitagliptin added to ongoing metformin therapy in type 2 diabetes patients who were inadequately controlled on metformin alone
    Meininger, G.
    Charbonnel, B.
    Karasik, A.
    Liu, J.
    Wu, M.
    Meehan, A.
    [J]. DIABETOLOGIA, 2006, 49 : 5 - 6
  • [23] Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
    Iijima, Hiroaki
    Kifuji, Takayuki
    Maruyama, Nobuko
    Inagaki, Nobuya
    [J]. ADVANCES IN THERAPY, 2015, 32 (08) : 768 - 782
  • [24] Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus
    Hermansen, Kjeld
    Mortensen, Lene S.
    [J]. DRUG SAFETY, 2007, 30 (12) : 1127 - 1142
  • [25] Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus
    Kjeld Hermansen
    Lene S. Mortensen
    [J]. Drug Safety, 2007, 30 : 1127 - 1142
  • [26] Risk of prostatitis in patients with type 2 diabetes: a retrospective database study of canagliflozin vs other antihyperglycaemic agents
    Yuan, Z.
    Jeffcoat, C.
    Ali, R. S.
    Ryan, P.
    Sena, A.
    Schuemie, M.
    Fonseca, S.
    [J]. DIABETOLOGIA, 2023, 66 (SUPPL 1) : S352 - S352
  • [27] Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus
    Inagaki, Nobuya
    Harashima, Shin-ichi
    Kaku, Kohei
    Kondo, Kazuoki
    Maruyama, Nobuko
    Otsuka, Makiko
    Kawaguchi, Yutaka
    Iijima, Hiroaki
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (04): : 812 - 820
  • [28] Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
    Fulcher, Greg
    Matthews, David R.
    Perkovic, Vlado
    de Zeeuw, Dick
    Mahaffey, Kenneth W.
    Weiss, Robert
    Rosenstock, Julio
    Capuano, George
    Desai, Mehul
    Shaw, Wayne
    Vercruysse, Frank
    Meininger, Gary
    Neal, Bruce
    [J]. DIABETES THERAPY, 2015, 6 (03) : 289 - 302
  • [29] Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
    Yale, J. -F.
    Bakris, G.
    Cariou, B.
    Nieto, J.
    David-Neto, E.
    Yue, D.
    Wajs, E.
    Figueroa, K.
    Jiang, J.
    Law, G.
    Usiskin, K.
    Meininger, G.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (10): : 1016 - 1027
  • [30] EFFICACY AND SAFETY OF CANAGLIFLOZIN AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Kaur, K.
    Likhar, N.
    Dang, A.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A56 - A57
12345